Axa
COGT icon

Axa’s Cogent Biosciences COGT Stock Holding History

Axa’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-285,210
Closed -$4.26M – 1152
2022
Q3 		$4.26M Sell
285,210
-299,784
-51% -$4.11M 0.02% 606
2022
Q2 		$5.28M Sell
584,994
-11,400
-2% -$77.8K 0.02% 565
2022
Q1 		$4.47M Buy
596,394
+7
+0% +$49 0.01% 670
2021
Q4 		$5.12M Buy
596,387
+7,130
+1% +$62K 0.01% 660
2021
Q3 		$4.96M Buy
589,257
+21,659
+4% +$166K 0.01% 683
2021
Q2 		$4.6M Sell
567,598
-800
-0.1% -$6.76K 0.01% 729
2021
Q1 		$4.99M Buy
568,398
+177,739
+45% +$1.71M 0.02% 711
2020
Q4 		$4.39M Buy
+390,659
New +$4.29M 0.01% 719

Other funds holding COGT

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Axa's COGT Position: Q4 2022 in Review

Axa sold out of Cogent Biosciences (COGT) in Q4 2022, closing a stake of 285,210 shares — an estimated $4.26M sold.

Axa first reported a position in COGT in Q4 2020 and held it in 8 quarters. The position peaked at $5.28M in Q2 2022. 135 funds tracked by Wall St. Rank hold COGT as of Q4 2022.

  • Axa reported no remaining Cogent Biosciences position as of Q4 2022 after selling out during the quarter.
  • Axa sold 285,210 Cogent Biosciences shares in Q4 2022, an estimated $4.26M.
  • Axa first reported a position in Cogent Biosciences in Q4 2020 and held it in 8 quarters.
  • Axa's Cogent Biosciences position peaked at $5.28M in Q2 2022.
  • 135 funds tracked by Wall St. Rank held Cogent Biosciences as of Q4 2022.

Based on Axa's 13F filing for Q4 2022, filed 14 Feb 2023.